Targeting the cGAS-STING Pathway for Cancer Immunotherapy: From Small-Molecule Agonists to Advanced Nanomaterials
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01263 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Zhibin Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Separation Membrane Materials, School of Chemistry & School of Chemical Engineering and Technology & School of Mater…. Hauptthemen laut MEDLINE: Nucleotidyltransferases, Immunotherapy, Neoplasms, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 169 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, Hubei Provincial Department of Education, National Natural Science Foundation of China.
Abstract (Originalsprache)
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway has emerged as a pivotal mediator of antitumor immunity, bridging innate and adaptive immune responses through its ability to sense cytoplasmic DNA and orchestrate cytokine production. This review comprehensively explores recent advancements in targeting this pathway for cancer immunotherapy, focusing on two key strategies: small-molecule agonists and nanomaterial-based therapeutics. Small-molecule agonists, including cyclic dinucleotide (CDN) derivatives and non-nucleotide compounds, have been engineered to overcome limitations such as enzymatic degradation and poor bioavailability. Candidates such as ADU-S100 and MSA-2 demonstrate enhanced STING activation and clinical potential. Concurrently, innovative nanoplatforms, which incorporate both inorganic materials, such as those based on manganese, zinc, or arsenic, and organic carriers, like liposomes, polymers, exosomes, and ferritin, leverage tumor microenvironment (TME)-responsive designs to amplify cGAS-STING signaling. These nanotherapeutics synergize DNA damage induction, immunogenic cell death, and immune checkpoint blockade to convert immunologically "cold" tumors into "hot" phenotypes. Despite progress, challenges persist in balancing pathway activation efficacy with systemic toxicity, optimizing systemic delivery for metastatic tumors, and ensuring long-term biocompatibility. Future directions emphasize the development of smart nanocarriers with spatiotemporal control, biomarker-driven patient stratification, and combinatorial regimens that integrate epigenetic or metabolic modulators. This review underscores the transformative potential of cGAS-STING-targeted therapies while outlining critical hurdles and interdisciplinary strategies to advance precision cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Separation Membrane Materials, School of Chemistry & School of Chemical Engineering and Technology & School of Material Science and Engineering, Tiangong University, Tianjin 300387, P. R…
- College of Nursing and Health Management, Wuhan Donghu College, Wuhan 430212, P. R. China.
- Key Laboratory of Catalysis and Energy Materials Chemistry (Ministry of Education) & Hubei Key Laboratory of Catalysis and Materials Science, South-Central Minzu University, Wuhan 430074, P. R. China.
ORCID-Profile: Zhibin Guo, Yi Liu, Yujiao Liu
Förderung
- Natural Science Foundation of Hubei Province
- Hubei Provincial Department of Education
- National Natural Science Foundation of China
Zitieren
APA
Guo, Z., Liu, T., Gao, Q., Wang, C., Wang, Q., Du, R., Liu, Y., Li, H., Huang, Y., Liu, Y., & Liu, Y. (2025). Targeting the cGAS-STING Pathway for Cancer Immunotherapy: From Small-Molecule Agonists to Advanced Nanomaterials. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01263
Vancouver
Guo Z, Liu T, Gao Q, Wang C, Wang Q, Du R, et al. Targeting the cGAS-STING Pathway for Cancer Immunotherapy: From Small-Molecule Agonists to Advanced Nanomaterials. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01263
BibTeX
@article{Guo2025,
author = {Guo, Zhibin and Liu, Tingting and Gao, Qichao and Wang, Caiyu and Wang, Qing and Du, Ruili and Liu, Yufei and Li, Hanping and Huang, Yan and Liu, Yi and Liu, Yujiao},
title = {Targeting the cGAS-STING Pathway for Cancer Immunotherapy: From Small-Molecule Agonists to Advanced Nanomaterials},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01263}
}
EUVIMED